The Prognostic Value of the Age-Adjusted Charlson Comorbidity Index Among the Elderly with Breast Cancer

Purpose This study aimed to assess the effect of comorbidities on prognosis using the Age-adjusted Charlson Comorbidity Index (ACCI) among the elderly with breast cancer (BC). Methods This study included 745 patients divided into two groups following the ACCI score (≤3 vs >3). Multivariate logistic regression analysis was conducted for all kinds of outcomes, including BC-specific death (BCSD) and non-breast cancer-specific death (NBCSD). The Kaplan–Meier curves were plotted, and survival analysis was conducted for disease-free survival (DFS), overall survival (OS), BC-specific survival (BCSS), and non-BCSS (NBCSS). Results A significantly higher NBCSD was found in the high-score (ACCI > 3) group than in the low-score (ACCI < 3) group (p = 0.032). The multivariate logistic regression analysis revealed ACCI score as an independent affecting factor for all-cause death (hazard ratio [HR] = 0.42, 95% confidence interval [CI]: 0.22–0.83, p = 0.012) and NBCSD (HR = 0.41, 95% CI: 0.20–0.87, p = 0.020). The Kaplan–Meier curves revealed statistical differences only in NBCSS between the two groups (p = 0.039). Subgroup analysis revealed a worse prognosis in the high-score group for OS and NBCSS among hormone receptor-positive participants and those who without undergoing axillary dissection or receiving chemotherapy (all p < 0.05). Multivariate Cox regression analysis revealed ACCI as an independent prognostic predictor for OS (HR = 2.18, 95% CI: 1.22–3.92, p = 0.009) and NBCSS (HR = 2.04, 95% CI: 1.02–4.08, p = 0.044). Conclusion ACCI was indeed an effective indicator of the effects of comorbidities on survival among elderly patients with BC. However, the co-effect from age and comorbidities was not significant enough on cancer-specific prognosis, although it exerted a significant effect on treatments received.

[1]  C. Kwak,et al.  The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma , 2020, Journal of Cancer Research and Clinical Oncology.

[2]  T. Yoshikawa,et al.  Impact of the Age-adjusted Charlson comorbidity index on the short- and long-term outcomes of patients undergoing curative gastrectomy for gastric cancer , 2019, Journal of Cancer.

[3]  C. Castro,et al.  Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer , 2019, International journal of cancer.

[4]  A. Garden,et al.  Age‐adjusted comorbidity and survival in locally advanced laryngeal cancer , 2018, Head and Neck.

[5]  Ling Chen,et al.  Impact of Comorbidity on Symptoms and Quality of Life Among Patients Being Treated for Breast Cancer. , 2018, Cancer nursing.

[6]  Y. Choi,et al.  Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients , 2018, PloS one.

[7]  E. Bastiaannet,et al.  Targeted therapy in older women with breast cancer - What's the target? , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  A. Tricco,et al.  Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. , 2017, Journal of geriatric oncology.

[9]  P. Kuppen,et al.  The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A FOCUS study analysis , 2016, Molecular oncology.

[10]  Chun-Ming Chang,et al.  Adjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery , 2016, PloS one.

[11]  D. Levine,et al.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. , 2015, Gynecologic oncology.

[12]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[13]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[14]  M. Elshaikh,et al.  Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. , 2013, Gynecologic oncology.

[15]  D. Bocalini,et al.  Isometric handgrip does not elicit cardiovascular overload or post-exercise hypotension in hypertensive older women , 2013, Clinical interventions in aging.

[16]  R. Akdoğan,et al.  Type 2 diabetes mellitus and prognosis in early stage breast cancer women , 2012, Medical Oncology.

[17]  A. Neugut,et al.  The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project , 2012, Cancer Causes & Control.

[18]  Laura Biganzoli,et al.  Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). , 2012, The Lancet. Oncology.

[19]  S. Dalton,et al.  Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008 , 2012, Breast Cancer Research and Treatment.

[20]  T. Byers,et al.  The influence of comorbidities on overall survival among older women diagnosed with breast cancer. , 2011, Journal of the National Cancer Institute.

[21]  L. Ngo,et al.  Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Guangyu Liu,et al.  Breast cancer in Chinese elderly women: pathological and clinical characteristics and factors influencing treatment patterns. , 2009, Critical reviews in oncology/hematology.

[23]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[24]  Jhi-Joung Wang,et al.  The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[25]  A. D. de Craen,et al.  Postoperative complications and survival of elderly breast cancer patients: a FOCUS study analysis , 2013, Breast Cancer Research and Treatment.

[26]  W. Cheung,et al.  Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.